← Leaderboards
Anh D Le
University Of California Los Angeles
$4,956,118
Attributed
$7,013,162
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $613.3K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,013,162 · 11
By mechanism
R01$4,603,633 · 2
S11$1,490,891 · 1
R21$446,250 · 1
R34$200,000 · 1
R03$163,000 · 1
K08$75,113 · 1
Top collaborators
- Songtao Shi7 shared
- Yufang Shi6 shared
- Stephen Elliott Feinberg2 shared
- Jason A Burdick1 shared
- Bert W O'Malley1 shared
- Thomas P Schaer1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- David T Wong$54,826,713
- Xiaofeng Zhou$2,882,296
- Shen Hu$531,923
- Reuben Han-Kyu Kim$4,789,352
- George T.j Huang$2,695,361
Others in their field
Top investigators on “Oral”
- Daniel R Kuritzkes · Brigham And Women'S Hospital$236,409,338
- Judith S. Currier · University Of California Los Angeles$134,347,732
- Constance Ann Benson · University Of California, San Diego$123,741,444
- Wafaa M. El-Sadr · Columbia University Health Sciences$92,413,650
- Myron S Cohen · Family Health International$91,263,426
- Robert A Wood · Johns Hopkins University$57,641,510
Research focus
OralMediatingBasePlayWound HealingSelf-RenewalCellsMolecularHuman TissueGeneticMorbidity - Disease RateProteinsParacrineImmuneInflammationIn VitroAnti-Inflammatory AgentsCell PhysiologyIn VivoPropertyHistologicAngiogenesisGrowth Factor ReceptorsCraniofacial
Grant awards (27)
Targeted inhibition of eIF5Ahpu suppresses tumor growth and M2-like TAM polarization in oral cancer$413,522
R01 · FY2025 · DE · contact PI
Targeted inhibition of eIF5Ahpu suppresses tumor growth and M2-like TAM polarization in oral cancer$431,912
R01 · FY2024 · DE · contact PI
Targeted inhibition of eIF5Ahpu suppresses tumor growth and M2-like TAM polarization in oral cancer$453,848
R01 · FY2023 · DE · contact PI
Targeted inhibition of eIF5Ahpu suppresses tumor growth and M2-like TAM polarization in oral cancer$469,285
R01 · FY2022 · DE · contact PI
Therapeutic Potential of Gingival mesenchymal Stem Cell-derived Extracellular Vesicles Enriched with MFG-E8 in Peripheral Nerve Regeneration$243,750
R21 · FY2021 · DE · contact PI
Therapeutic Potential of Gingival mesenchymal Stem Cell-derived Extracellular Vesicles Enriched with MFG-E8 in Peripheral Nerve Regeneration$202,500
R21 · FY2020 · DE · contact PI
Penn Multidisciplinary Consortium: Personalized Dental, Oral and Craniofacial Tissue Regeneration$200,000
R34 · FY2015 · DE · contact PI
GINGIVA DERIVED MSCS: ROLE IN IMMUNOMODULATION AND TISSUE REGENERATION$506,657
R01 · FY2013 · DE · contact PI
GINGIVA DERIVED MSCS: ROLE IN IMMUNOMODULATION AND TISSUE REGENERATION$544,458
R01 · FY2012 · DE · contact PI
GINGIVA DERIVED MSCS: ROLE IN IMMUNOMODULATION AND TISSUE REGENERATION$17,568
R01 · FY2012 · DE · contact PI
GINGIVA DERIVED MSCS: ROLE IN IMMUNOMODULATION AND TISSUE REGENERATION$574,256
R01 · FY2011 · DE · contact PI
GINGIVA DERIVED MSCS: ROLE IN IMMUNOMODULATION AND TISSUE REGENERATION$597,450
R01 · FY2010 · DE · contact PI
AAOMS RESEARCH SUMMIT ON TRANSLATIONAL RESEARCH FROM BENCH TO BEDSIDE$7,000
R13 · FY2010 · DE · contact PI
GINGIVA DERIVED MSCS: ROLE IN IMMUNOMODULATION AND TISSUE REGENERATION$594,677
R01 · FY2009 · DE · contact PI
BOWMAN-BIRK INHIBITOR CONCENTRATE & ORAL LEUKOPLAKIA: PHASE IIB TRIAL (UNIVER$11,594
M01 · FY2009 · RR · contact PI
AAOMS RESEARCH SUMMIT ON TRANSLATIONAL RESEARCH FROM BENCH TO BEDSIDE$7,000
R13 · FY2009 · DE · contact PI
INFLAMMATORY BIOMARKERS AND HPV-ASSOCIATED ORAL PRE-CANCER$81,500
R03 · FY2008 · CA · contact PI
BOWMAN-BIRK INHIBITOR CONCENTRATE & ORAL LEUKOPLAKIA: PHASE IIB TRIAL (UNIVER$4,806
M01 · FY2008 · RR · contact PI
INFLAMMATORY BIOMARKERS AND HPV-ASSOCIATED ORAL PRE-CANCER$81,500
R03 · FY2007 · CA · contact PI
BOWMAN-BIRK INHIBITOR CONCENTRATE & ORAL LEUKOPLAKIA: PHASE IIB TRIAL (UNIVER$3,875
M01 · FY2007 · RR · contact PI
HYPOXIA REGULATION OF VEGF/VEGF RECEPTORS IN KELOIDS$312,918
S11 · FY2004 · AR
HYPOXIA REGULATION OF VEGF/VEGF RECEPTORS IN KELOIDS$13,784
S11 · FY2004 · AR
HYPOXIA REGULATION OF VEGF/VEGF RECEPTORS IN KELOIDS$261,112
S11 · FY2003 · AR
HYPOXIA REGULATION OF VEGF/VEGF RECEPTORS IN KELOIDS$289,289
S11 · FY2002 · AR
HYPOXIA REGULATION OF VEGF/VEGF RECEPTORS IN KELOIDS$311,188
S11 · FY2001 · AR
HYPOXIA REGULATION OF VEGF/VEGF RECEPTORS IN KELOIDS$302,600
S11 · FY2000 · AR
REGULATION OF WOUND ANGIOGENESIS--VEGF &VEGF RECEPTORS$75,113
K08 · FY2000 · DE